Metabolic Bone Disease in Inflammatory Bowel Disease

Journal of Clinical Gastroenterology

Volumn 38, Issue 3, 2004, Pages 218-224

  Harpavat, Manisha ^a   Keljo, David J ^a   Regueiro, Miguel D ^b,c  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Bone demineralization; Crohn disease; Inflammatory bowel disease; Metabolic bone disease; Osteoporosis; Pediatric inflammatory bowel disease

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CORTICOSTEROID; CYTOKINE; ESTROGEN; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

BONE DENSITY; BONE MINERAL; BREAST TENDERNESS; CANCER RISK; CROHN DISEASE; DIAGNOSTIC APPROACH ROUTE; DOSE RESPONSE; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSPEPSIA; ENTERITIS; ESOPHAGITIS; EXERCISE; HOT FLUSH; HUMAN; LEG CRAMP; MALNUTRITION; NOSE INJURY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SCORING SYSTEM; SIDE EFFECT; STANDARD; THROMBOEMBOLISM; ULCERATIVE COLITIS; VAGINA BLEEDING; WEIGHT BEARING;

BONE DENSITY; DIPHOSPHONATES; GLUCOCORTICOIDS; HUMANS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; MALNUTRITION; OSTEOPOROSIS; RISK FACTORS;

EID: 1242352559     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200403000-00005     Document Type: Review

References (74)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-795.
2. Looker AC, Orwoll ES, Johnston CC Jr, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12:1761-1768.
3. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94:646-650.
4. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285:320-323.
5. Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:24-35.
6. Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut. 1997;40:228-233.
7. Andreassen H, Rungby J, Dahlerup JF, et al. Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol. 1997;32:1247-1255.
8. Ardizzone S, Bollani S, Bettica P, et al. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J Intern Med. 2000;247:63-70.
9. Papaioannou A, Ferko NC, Adachi JD. All patients with inflammatory bowel disease should have bone density assessment: pro. Inflamm Bowel Dis. 2001;7:158-162.
10. Jahnsen J, Falch JA, Aadland E, et al. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut. 1997;40:313-319.
11. Schoon EJ, van Nunen AB, Wouters RS et al. Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. Stand J Gastroenterol. 2000;232:43-47.
12. Haugeberg G, Vetvik K, Stallemo A, et al. Bone density reduction in patients with Crohn disease and associations with demographic and disease variables: cross-sectional data from a population-based study. Scand J Gastroenterol. 2001;36:759-765.
13. Bernstein CN, Seeger LL, Sayre JW, et al. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res. 1995;10:250-256.
14. Pollak RD, Karmeli F, Eliakim R, et al. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol. 1998;93:1483-1490.
15. Pigot F, Roux C, Chaussade S, et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci. 1992;37:1396-1403.
16. Roux C, Abitbol V, Chaussade S, et al. Bone loss in patients with inflammatory bowel disease: a prospective study. Osteoporos Int. 1995;5:156-160.
17. Robinson RJ, al-Azzawi F, Iqbal SJ, et al. Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci. 1998;43:2500-2506.
18. Silvennoinen JA, Karttunen TJ, Niemela SE, et al. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut. 1995;37:71-76.
19. Schulte C, Dignass AU, Mann K, et al. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis. 1998;4:268-275.
20. Ghosh S, Cowen S, Hannan WJ, et al. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology. 1994;107:1031-1039.
21. Lee SH, Kim HJ, Yang SK, et al. Decreased trabecular bone mineral density in newly diagnosed inflammatory bowel disease patients in Korea. J Gastroenterol Hepatol. 2000;15:512-518.
22. Schoon EJ, Blok BM, Geerling BJ, et al. Bone mineral density in patients with recently diagnosed inflammatory bowel disease [comment]. Gastroenterology. 2000;119:1203-1208.
23. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:795-841.
24. Loftus EV Jr, Crowson CS, Sandborn WJ, et al. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology. 2002;123:468-475.
25. Favus M. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 4 ed. Philadelphia: Lippincott Williams & Wilkins; 1999.
26. Riggs BL. Vitamin D-receptor genotypes and bone density. N Engl J Med. 1997;337:125-126.
27. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995;332:305-311.
28. Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001;286:2815-2822.
29. Heaney RP, Abrams S, Dawson-Hughes B, et al. Peak bone mass. Osteoporos Int. 2000;11:985-1009.
30. Stewart TL, Ralston SH. Role of genetic factors in the pathogenesis of osteoporosis. J Endocrinol. 2000;166:235-245.
31. Uitterlinden AG, Weel AE, Burger H, et al. Interaction between the vitamin D receptor gene and collagen type 1alpha 1 gene in susceptibility for fracture. J Bone Miner Res. 2001;16:379-385.
32. Canalis E. Clinical review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab. 1996;81:3441-3447.
33. Weinstein RS, Manolagas SC. Apoptosis and osteoporosis. Am J Med. 2000;108:153-164.
34. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990;112:352-364.
35. Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res. 1999;14:1061-1066.
36. Pearce G, Tabensky DA, Delmas PD, et al. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab. 1998;83:801-806.
37. Nielsen HK, Thomsen K, Eriksen EF, et al. The effects of high-dose glucocorticoid administration on serum bone gamma carboxyglutamic acid-containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects. Bone Miner. 1988;4:105-113.
38. Adler RA, Rosen CJ. Glucocorticoids and osteoporosis. Endocrinol Metab Clin North Am. 1994;23:641-654.
39. Reid IR, Heap SW. Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med. 1990;150:2545-2548.
40. Compston JE. Review article: osteoporosis, corticosteroids and inflammatory bowel disease. Aliment Pharmacol Ther. 1995;9:237-250.
41. Fries W, Dinca M, Luisetto G, et al. Calcaneal ultrasound bone densitometry in inflammatory bowel disease - a comparison with double x-ray densitometry of the lumbar spine. Am J Gastroenterol. 1998;93:2339-2344.
42. Cino M, Greenberg GR. Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am J Gastroenterol. 2002;97:915-921.
43. Harpavat M, Keljo DJ. Perspectives on osteoporosis in pediatric inflammatory bowel disease. Curr Gastroenterol Rep. 2003;5:225-232.
44. Semeao EJ, Jawad AF, Zemel BS, et al. Bone mineral density in children and young adults with Crohn's disease. Inflamm Bowel Dis. 1999;5:161-166.
45. Boot AM, Bouquet J, Krenning EP, et al. Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. Gut. 1998;42:188-194.
46. Thearle M, Horlick M, Bilezikian JP, et al. Osteoporosis: an unusual presentation of childhood Crohn's disease. J Clin Endocrinol Metab. 2000;85:2122-2126.
47. Nielsen OH, Vainer B, Madsen SM, et al. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol. 2000;95:359-367.
48. MacDonald BR, Gowen M. Cytokines and bone. Br J Rheumatol. 1992;31:149-155.
49. Scheidt-Nave C, Bismar H, Leidig-Bruckner G, et al. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab. 2001;86:2032-2042.
50. Azuma Y, Kaji K, Katogi R, et al. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem. 2000;275:4858-4864.
51. Kaji K, Katogi R, Azuma Y, et al. Tumor necrosis factor alpha-induced osteoclastogenesis requires tumor necrosis factor receptor-associated factor 6. J Bone Miner Res. 2001;16:1593-1599.
52. Gilbert L, He X, Farmer P, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology. 2000;141:3956-3964.
53. Hofbauer LC, Khosla S, Dunstan CR, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res. 2000;15:2-12.
54. Vogelsang H, Klamert M, Resch H, et al. Dietary vitamin D intake in patients with Crohn's disease. Wien Klin Wochenschr. 1995;107:578-581.
55. Silvennoinen J, Lamberg-Allardt C, Karkkainen M, et al. Dietary calcium intake and its relation to bone mineral density in patients with inflammatory bowel disease. J Intern Med. 1996;240:285-292.
56. Southard RN, Morris JD, Mahan JD, et al. Bone mass in healthy children: measurement with quantitative DXA. Radiology. 1991;179:735-738.
57. Robinson RJ, Carr I, Iqbal SJ, et al. Screening for osteoporosis in Crohn's disease. A detailed evaluation of calcaneal ultrasound. Eur J Gastroenterol Hepatol. 1998;10:137-140.
58. Mughal MZ, Ward K, Qayyum N, et al. Assessment of bone status using the contact ultrasound bone analyser. Arch Dis Child. 1997;76:535-536.
59. Frost ML, Blake GM, Fogelman I. Quantitative ultrasound and bone mineral density are equally strongly associated with risk factors for osteoporosis. J Bone Miner Res. 2001;16:406-416.
60. Jahnsen J, Falch JA, Mowinckel P, et al. Ultrasound measurements of calcaneus for estimation of skeletal status in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999;34:790-797.
61. Looker AC, Bauer DC, Chesnut CH III, et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int. 2000;11:467-480.
62. Bauer DC, Sklarin PM, Stone KL, et al. Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J Bone Miner Res. 1999;14:1404-1410.
63. Melton LJ III, Khosla S, Atkinson EJ, et al. Relationship of bone turnover to bone density and fractures. J Bone Miner Res. 1997;12:1083-1091.
64. Greenspan SL, Rosen HN, Parker RA. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type I predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab. 2000;85:3537-3540.
65. Dresner-Pollak R, Karmeli F, Eliakim R, et al. Increased urinary N-telopeptide cross-linked type I collagen predicts bone loss in patients with inflammatory bowel disease. Am J Gastroenterol. 2000;95:699-704.
66. Nielsen HK, Charles P, Mosekilde L. The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects. J Clin Endocrinol Metab. 1988;67:1025-1030.
67. Issenman RM, Atkinson SA, Radoja C, et al. Longitudinal assessment of growth, mineral metabolism, and bone mass in pediatric Crohn's disease. J Pediatr Gastroenterol Nutr. 1993;17:401-406.
68. Cowan FJ, Warner JT, Dunstan FD, et al. Inflammatory bowel disease and predisposition to osteopenia. Arch Dis Child. 1997;76:325-329.
69. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2000.
70. Bernstein CN, Seeger LL, Anton PA, et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther. 1996;10:777-786.
71. Vogelsang H, Ferenci P, Resch H, et al. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol. 1995;7:609-614.
72. Clements D, Compston JE, Evans WD, et al. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut. 1993;34:1543-1546.
73. Haderslev KV, Tjellesen L, Sorensen HA, et al. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology. 2000;119:639-646.
74. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-1541.